Efficacy of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography in restaging muscle-invasive bladder cancer following radical cystectomy

Öztürk,Hakan; Karapolat,İnanç

doi:10.3892/etm.2015.2187

Efficacy of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography in restaging muscle-invasive bladder cancer following radical cystectomy

Authors:
- Hakan Öztürk
- İnanç Karapolat
View Affiliations

Affiliations: Department of Urology, School of Medicine, Sifa University, Izmir 35240, Turkey, Department of Nuclear Medicine, School of Medicine, Sifa University, Izmir 35240, Turkey
Published online on: January 16, 2015 https://doi.org/10.3892/etm.2015.2187
Pages: 717-724
Copyright: © Öztürk et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to retrospectively evaluate the contribution and effectiveness of 18F‑fluorodeoxyglucose‑positron emission tomography/computed tomography (18F‑FDG‑PET/CT) scans in the restaging of patients following radical cystectomy due to muscle‑invasive bladder carcinoma (MIBC). A total of 51 patients (45 males and six females) who underwent radical cystectomy due to invasive bladder cancer, and had an 18F‑FDG‑PET/CT scan for restaging between July 2007 and April 2013, were included in the present study. The mean age was 62.3±9.79 years (range, 40‑82 years). Patients underwent a six‑hour fast prior to scanning, and whole‑body PET scanning from the skull base to the upper thighs was performed ~1 h after the intravenous injection of 555 MBq 18F‑FDG. Whole‑body CT scanning was performed in a cranio‑caudal direction. 18F‑FDG‑PET images were reconstructed using CT data for attenuation correction. Histopathology or clinical follow‑up was used to confirm any suspicious recurrent or metastatic lesions. The results for sensitivity, specificity, positive predictive value (PPV), negative predictive value and accuracy of 18F‑FDG‑PET/CT were 92, 83, 94, 77 and 90%, respectively. In conclusion, 18F‑FDG‑PET/CT efficiently detects local recurrence and distant metastases with high sensitivity and PPV in the restaging of patients who underwent radical cystectomy due to invasive bladder cancer. This procedure could play an important role in rendering decisions regarding radiotherapy or chemotherapy and post‑operative follow‑up, and could influence the entire decision‑making process.

View Figures

View References

1	Ploeg M, Aben KK and Kiemeney LA: The present and future burden of urinary bladder cancer in the world. World J Urol. 27:289–293. 2009. View Article : Google Scholar : PubMed/NCBI
2	Abdollah F, Gandaglia G, Thuret R, et al: Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. Cancer Epidemiol. 37:219–225. 2013. View Article : Google Scholar : PubMed/NCBI
3	Kaufman DS, Shipley WU and Feldman AS: Bladder cancer. Lancet. 374:239–249. 2009. View Article : Google Scholar : PubMed/NCBI
4	Vaidya A, Soloway MS, Hawke C, et al: De novo muscle invasive bladder cancer: is there a change in trend? J Urol. 165:47–50. 2001. View Article : Google Scholar
5	Stein JP, Lieskovsky G, Cote R, et al: Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 19:666–675. 2001.PubMed/NCBI
6	Simone G, Papalia R, Ferriero M, et al: Stage-specific impact of extended versus standard pelvic lymph node dissection in radical cystectomy. Int J Urol. 20:390–397. 2013. View Article : Google Scholar
7	Barentsz JO, Jager GJ, Witjes JA and Ruijs JH: Primary staging of urinary bladder carcinoma: the role of MR imaging and a comparison with CT. Eur Radiol. 6:129–133. 1996. View Article : Google Scholar
8	Kundra V and Silverman PM: Imaging in oncology from the University of Texas M. D. Anderson Cancer Center. Imaging in the diagnosis, staging, and follow-up of cancer of the urinary bladder. AJR Am J Roentgenol. 180:1045–1054. 2003. View Article : Google Scholar : PubMed/NCBI
9	Barentsz JO, Engelbrecht MR, Witjes JA, et al: MRI of the male pelvis. Eur Radiol. 9:1722–1736. 1999. View Article : Google Scholar
10	Shariat SF, Karakiewicz PI, Palapattu GS, et al: Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol. 176:2414–2422. 2006. View Article : Google Scholar : PubMed/NCBI
11	Gillies RJ, Robey I and Gatenby RA: Causes and consequences of increased glucose metabolism of cancers. J Nucl Med. 49(Suppl 2): 24S–42S. 2008. View Article : Google Scholar : PubMed/NCBI
12	Smith TA: Mammalian hexokinases and their abnormal expression in cancer. Br J Biomed Sci. 57:170–178. 2000.PubMed/NCBI
13	Harney JV, Wahl RL, Liebert M, Kuhl DE, Hutchins GD, Wedemeyer G and Grossman HB: Uptake of 2-deoxy, 2-(¹⁸F) fluoro-D-glucose in bladder cancer: animal localization and initial patient positron emission tomography. J Urol. 145:279–283. 1991.PubMed/NCBI
14	Drieskens O, Oyen R, Van Poppel H, Vankan Y, Flamen P and Mortelmans L: FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging. 32:1412–1417. 2005. View Article : Google Scholar : PubMed/NCBI
15	Apolo AB, Riches J, Schöder H, Akin O, Trout A, Milowsky MI and Bajurin DF: Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. J Clin Oncol. 28:3973–3978. 2010. View Article : Google Scholar : PubMed/NCBI
16	Kibel AS, Dehdashti F, Katz MD, Klim AP, Grubb RL, Humphrey PA, et al: Prospective study of [¹⁸F] fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol. 27:4314–4320. 2009. View Article : Google Scholar : PubMed/NCBI
17	Lu YY, Chen JH, Liang JA, Wang HY, Lin CC, Lin WY and Kao CH: Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis. Eur J Radiol. 81:2411–2416. 2012. View Article : Google Scholar
18	Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR, Wan CN and Wolf AP: Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [¹⁸F] 2-deoxy-2-fluoro-D-glucose. J Nucl Med. 19:1154–1161. 1978.PubMed/NCBI
19	Kumar R, Zhuang H and Alavi A: PET in the management of urologic malignancies. Radiol Clin North Am. 42:1141–1153. 2004. View Article : Google Scholar : PubMed/NCBI
20	Caracó C, Aloj L, Chen LY, Chou JY and Eckelman WC: Cellular release of [¹⁸F]2-fluoro-2-deoxyglucose as a function of the glucose-6-phosphatase enzyme system. J Biol Chem. 275:18489–18494. 2000. View Article : Google Scholar
21	Lin EC and Alavi A: Urologic tumors. PET and PET/CT: A Clinical Guide. 2nd edition. Thieme; New York, NY: pp. 204–211. 2009
22	Kosuda S, Kison PV, Greenough R, Grossman HB and Wahl RL: Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer. Eur J Nucl Med. 24:615–620. 1997.PubMed/NCBI
23	López-Gandul S, Pérez-Moure G, García-Garzón JR, et al: Intravenous furosemide injection during ¹⁸F-FDG PET acquisition. J Nucl Med Technol. 34:228–231. 2006.
24	Anjos DA, Etchebehere EC, Ramos CD, Santos AO, Albertotti C and Camargo EE: ¹⁸F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer. J Nucl Med. 48:764–770. 2007. View Article : Google Scholar : PubMed/NCBI
25	Harkirat S, Anand S and Jacob M: Forced diuresis and dual-phase F-fluorodeoxyglucose-PET/CT scan for restaging of urinary bladder cancers. Indian J Radiol Imaging. 20:13–19. 2010. View Article : Google Scholar : PubMed/NCBI
26	Lodde M, Lacombe L, Friede J, Morin F, Saourine A and Fradet Y: Evaluation of fluorodeoxyglucose positron-emission tomography with computed tomography for staging of urothelial carcinoma. BJU Int. 106:658–663. 2010. View Article : Google Scholar : PubMed/NCBI
27	Swinnen G, Maes A, Pottel H, Vanneste A, Billiet I, et al: FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Eur Urol. 57:641–647. 2010. View Article : Google Scholar
28	Bouchelouche K, Turkbey B and Choyke PL: PET/CT and MRI in bladder cancer. J Cancer Sci Ther. (Suppl 14)30:76922012.
29	Jadvar H, Quan V, Henderson RW and Conti PS: [F-18]-Fluorodeoxyglucose PET and PET-CT in diagnostic imaging evaluation of locally recurrent and metastatic bladder transitional cell carcinoma. Int J Clin Oncol. 13:42–47. 2008. View Article : Google Scholar : PubMed/NCBI
30	Goodfellow H, Viney Z, Hughes P, Rankin S, Rottenberg G, Hughes S, et al: Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer. BJU Int. 114:389–395. 2014.
31	Mertens LS, Mir MC, Scott AM, Lee ST, Fioole-Bruining A, Vegt E, et al: ¹⁸F-fluorodeoxyglucose--positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer. Urology. 83:393–398. 2014. View Article : Google Scholar : PubMed/NCBI
32	Jana S and Blaufox MD: Nuclear medicine studies of the prostate, testes, and bladder. Semin Nucl Med. 36:51–72. 2006. View Article : Google Scholar
33	Maurer T, Souvatzoglou M, Kübler H, Opercan K, Schmidt S, et al: Diagnostic efficacy of [¹¹C]choline positron emission tomography/computed tomography compared with conventional computed tomography in lymph node staging of patients with bladder cancer prior to radical cystectomy. Eur Urol. 61:1031–1038. 2012. View Article : Google Scholar
34	Golan S, Sopov V, Baniel J and Groshar D: Comparison of ¹¹C-choline with ¹⁸F-FDG in positron emission tomography/computerized tomography for staging urothelial carcinoma: a prospective study. J Urol. 186:436–441. 2011. View Article : Google Scholar : PubMed/NCBI
35	Ahlström H, Malmström PU, Letocha H, Andersson J, Långström B and Nilsson S: Positron emission tomography in the diagnosis and staging of urinary bladder cancer. Acta Radiol. 37:180–185. 1996. View Article : Google Scholar : PubMed/NCBI
36	Schoder H, Ong SC, Reuter VE, Cai S, Burnazi E, et al: Initial Results with [¹¹]C-acetate positron emission tomography/computed tomography (PET/CT) in the staging of urinary bladder cancer. Mol Imaging Biol. 14:245–251. 2012. View Article : Google Scholar
37	El Fakhri G, Surti S, Trott CM, et al: Improvement in lesion detection with whole-body oncologic time-of-flight PET. J Nucl Med. 52:347–353. 2011. View Article : Google Scholar : PubMed/NCBI